← Leaderboards
Kristine B. Patterson
University Of North Carolina Chapel Hill
$1,443,950
Attributed
$1,443,950
Total exposure
25
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $368.3K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$1,443,950 · 25
By mechanism
M01$782,800 · 24
K23$661,150 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Angela D Kashuba$21,136,729
- Kim L Brouwer$15,343,248
- Andrew L Lee$10,585,321
- Kelly Evenson$4,679,547
- Linda M Nicholas$1,559,955
Others in their field
Top investigators on “Institution”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,187,810,557
- Leonard Freedman · Leidos Biomedical Research, Inc.$835,530,754
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$566,554,288
- Bambra Strokes · Ppd Development Lp$526,656,217
Research focus
InstitutionResearch PersonnelFundingUnited States National Institutes Of HealthResourcesPharmaceutical PreparationsGrantComputer Retrieval Of Information On Scientific Projects DatabaseSourceWomanClinical TrialsAnti-Hiv AgentsDoseAffectPurposePlasmaProtease InhibitorToxic EffectAnti-Retroviral AgentsHormonesBloodDrug KineticsBaseClinical Research
Grant awards (32)
Sex, Aging and Antiretroviral Pharmacology$132,230
K23 · FY2012 · AI · contact PI
Sex, Aging and Antiretroviral Pharmacology$132,230
K23 · FY2011 · AI · contact PI
Sex, Aging and Antiretroviral Pharmacology$132,230
K23 · FY2010 · AI · contact PI
Sex, Aging and Antiretroviral Pharmacology$132,230
K23 · FY2009 · AI · contact PI
CLINICAL TRIAL: AACTG 5202 - PHASE IIIB TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANA$211,816
M01 · FY2008 · RR · contact PI
Sex, Aging and Antiretroviral Pharmacology$132,230
K23 · FY2008 · AI · contact PI
CLINICAL TRIAL: SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACO AMONG HIV-1 MEN$16,993
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: SCH47690 IN HIV-INFECTED, TREATMENT EXPERIENCED SUBJECTS$3,642
M01 · FY2008 · RR · contact PI
CID 0705 - VACCINE SCREENING REGISTRY$2,427
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: AACTG 5188 - PHASE II TRANSDERMAL CONTRACEPTIVE SYSTEM IN HIV-1$606
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE II STUDY TO COMPARE TWICE DAILY AND ONCE DAILY THERAPY AND$606
M01 · FY2008 · RR · contact PI
AACTG 5202 - PHASE IIIB TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVI$308,814
M01 · FY2007 · RR · contact PI
AACTG 5188 - PHASE II TRANSDERMAL CONTRACEPTIVE SYSTEM IN HIV-1 WOMEN$5,720
M01 · FY2007 · RR · contact PI
IMMUNOLOGIC AND VIROLOGIC DIFFERENCES BETWEEN PRE- AND POST-MEN HIV WOMEN$3,431
M01 · FY2007 · RR · contact PI
PHASE II STUDY TO COMPARE TWICE DAILY AND ONCE DAILY THERAPY AND SELF-ADMINISTER$3,431
M01 · FY2007 · RR · contact PI
SCH47690 IN HIV-INFECTED, TREATMENT EXPERIENCED SUBJECTS$2,289
M01 · FY2007 · RR · contact PI
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACO AMONG HIV-1 MEN AND WOMEN$1,143
M01 · FY2007 · RR · contact PI
PK INTERACTIONS BETWEEN DMPA, DEPO-PROVERA AND SELECTED PROTEASE INHIBS$1,143
M01 · FY2007 · RR · contact PI
SCH47690 IN HIV-INFECTED, TREATMENT EXPERIENCED SUBJECTS$40,264
M01 · FY2006 · RR · contact PI
PHASE II STUDY TO COMPARE TWICE DAILY AND ONCE DAILY THERAPY AND SELF-ADMINISTER$30,198
M01 · FY2006 · RR · contact PI
IMMUNOLOGIC AND VIROLOGIC DIFFERENCES BETWEEN PRE- AND POST-MEN HIV WOMEN$25,164
M01 · FY2006 · RR · contact PI
PHASE I/II TRIAL OF ANTI-HIV ACTIVITY AMP; SAFETY OF MIFEPRISTONE (AACTG 5200)$22,144
M01 · FY2006 · RR · contact PI
AACTG 5202 - PHASE IIIB TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVI$21,139
M01 · FY2006 · RR · contact PI
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN$4,025
M01 · FY2006 · RR · contact PI
AACTG 5188 - PHASE II TRANSDERMAL CONTRACEPTIVE SYSTEM IN HIV-1 WOMEN$2,014
M01 · FY2006 · RR · contact PI
VIROLOGIC AND IMMUNOLOGIC CHANGES IN HIV-INFECTED WOMEN DURING POSTPARTUM$1,006
M01 · FY2006 · RR · contact PI
PHASE II STUDY TO COMPARE TWICE DAILY AND ONCE DAILY THERAPY AND SELF-ADMINISTER$37,267
M01 · FY2005 · RR
THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN: AIDS$13,250
M01 · FY2005 · RR
SCH47690 IN HIV-INFECTED, TREATMENT EXPERIENCED SUBJECTS$10,765
M01 · FY2005 · RR
PK INTERACTIONS BETWEEN DMPA, DEPO-PROVERA AND SELECTED PROTEASE INHIBS$827
M01 · FY2005 · RR
PK INTERACTIONS BETWEEN DMPA, DEPO-PROVERA AND SELECTED PROTEASE INHIBS$11,091
M01 · FY2004 · RR
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN$1,585
M01 · FY2004 · RR